美股招股观察

How to Choose an Industry Classification for a US Listing: Strategic Considerations for SIC and NAICS Codes

The SEC’s Division of Corporation Finance issued a Staff Legal Bulletin (SLB 14M) in March 2025 clarifying the circumstances under which companies may retroactively change their Standard Industrial Classification (SIC) code after an F-1 or S-1 filing. This bulletin, which supersedes prior guidance from 2021, directly impacts the timeline for confidential submissions under the EDGAR system and the scope of review a registrant receives. For Hong Kong issuers targeting a NYSE or NASDAQ listing in 2025–2026, the choice of SIC and NAICS code is no longer a purely administrative checkbox — it determines the reviewing SEC division (e.g., the Office of Life Sciences or the Office of Industrial Applications and Services), the applicable industry-specific disclosure requirements under Regulation S-K, and even the fee structure under the SEC’s new pay-to-play rules. An incorrect or non-standard code can trigger a full comment letter cycle, delaying the IPO by 6–10 weeks and adding USD 150,000–300,000 in legal and advisory costs, based on data from the SEC’s 2024 filing statistics. This article examines the strategic, regulatory, and operational factors that CFOs and their counsel must weigh when selecting SIC and NAICS codes for a US listing.

The Regulatory Architecture: SIC and NAICS in the SEC Framework

The SEC mandates that all registrants on EDGAR select a four-digit SIC code from the Standard Industrial Classification Manual (1987 revision). The North American Industry Classification System (NAICS), adopted in 1997 for statistical purposes by the US Office of Management and Budget, is not directly used by the SEC for filing classification but is required by the US Census Bureau for certain economic data submissions. For Hong Kong issuers, the interaction between these two systems creates a compliance gap that can lead to misclassification.

SIC Code as the Primary Gatekeeper

The SEC’s Division of Corporation Finance assigns each filing to one of 12 review offices based on the SIC code. For example, SIC codes 2834 (Pharmaceutical Preparations) and 2836 (Biological Products) route filings to the Office of Life Sciences, which applies heightened scrutiny to clinical trial disclosures and revenue recognition under ASC 606 for milestone payments. A Hong Kong biotech issuer using SIC 2834 must ensure that its prospectus includes a detailed discussion of FDA or NMPA approval timelines, patient enrollment numbers, and risk factors specific to Phase III trials — requirements that do not apply to SIC 8731 (Commercial Physical and Biological Research), which routes to the Office of Industrial Applications and Services and focuses on contract revenue and grant accounting.

The SEC’s 2024 annual report on filing reviews indicates that the Office of Life Sciences completes approximately 65% of its reviews within 30 days, compared to 78% for the Office of Industrial Applications and Services. This 13-percentage-point difference translates into a tangible time-to-market advantage for issuers that can legitimately use a non-life-sciences SIC code. However, the SEC’s SLB 14M explicitly warns against “SIC code shopping” — a practice where a company selects a code that does not reflect its primary business activity to obtain a more favourable review office. The bulletin states that the SEC may reclassify a filing and issue a comment letter requesting a corrected SIC code, which resets the review clock.

NAICS Code and Cross-Border Data Consistency

NAICS codes are structured hierarchically with six digits, providing greater granularity than SIC codes. For a Hong Kong issuer, the NAICS code is relevant for two reasons. First, the US Bureau of Economic Analysis uses NAICS to determine whether a foreign issuer qualifies for certain exemptions under the Investment Company Act of 1940. Second, the Hong Kong Census and Statistics Department maps its own industry classification (HSIC) to NAICS for trade and investment data. A mismatch between the HSIC code used in Hong Kong filings (e.g., under the Companies Ordinance, Cap. 622) and the NAICS code filed with the SEC can raise red flags during the SEC’s review of the issuer’s business description under Item 101 of Regulation S-K.

The SEC’s 2023 guidance on cross-border filings (CF Disclosure Guidance Topic 10) requires that the NAICS code be consistent with the issuer’s primary revenue-generating activity as disclosed in the audited financial statements. For a Hong Kong-based logistics company that derives 60% of its revenue from freight forwarding (NAICS 488510) and 40% from warehousing (NAICS 493110), the SEC expects the code that corresponds to the largest revenue stream, not the highest growth segment. Issuers that attempt to use NAICS 541614 (Process, Physical Distribution, and Logistics Consulting Services) to position themselves as a technology-enabled logistics platform have faced comment letters requiring reclassification to the operational code.

Strategic Implications for Hong Kong Issuers Across Sectors

The choice of SIC and NAICS codes carries material consequences for valuation, peer group selection, and investor perception. Hong Kong issuers must navigate the tension between a code that accurately reflects their business and one that positions them in a more favourable industry cohort.

Technology-Enabled Services vs. Traditional Industries

A Hong Kong fintech company that operates a digital payments platform (SIC 7374, Computer Processing and Data Preparation Services) faces a different regulatory burden than one classified under SIC 6099 (Functions Related to Deposit Banking, Not Elsewhere Classified). The SEC’s Office of Technology (SIC 7370–7379) typically requires less granular disclosure on regulatory licenses and money transmitter laws than the Office of Finance (SIC 6000–6199). However, the SEC’s 2024 review of fintech filings found that 23% of issuers using SIC 7374 received comment letters asking for clarification on whether they should be classified under SIC 6099, based on the nature of their money transmission activities.

The NAICS code amplifies this issue. NAICS 522320 (Financial Transactions Processing, Reserve, and Clearinghouse Activities) is the correct code for a payment processor that holds customer funds, while NAICS 518210 (Data Processing, Hosting, and Related Services) applies to a pure software platform. The distinction turns on whether the issuer has a money transmitter license in any US state — a fact that must be disclosed under Item 103 of Regulation S-K (legal proceedings). A Hong Kong fintech issuer that holds a Money Service Operator license from the Hong Kong Police Force under the Anti-Money Laundering and Counter-Terrorist Financing Ordinance (Cap. 615) must disclose this in the prospectus and map it to the relevant US state licensing requirements.

Biotech and Life Sciences: The SIC 2834 vs. 8731 Decision

For a Hong Kong biotech issuer listed on the HKEX under Chapter 18A (Biotech Companies), the SIC code selection is one of the most consequential decisions in the F-1 drafting process. SIC 2834 (Pharmaceutical Preparations) triggers the SEC’s industry guide for pharmaceutical companies, which requires disclosure of:

  • A pipeline table with all clinical trials, including phase, indication, and enrollment numbers
  • A discussion of each product candidate’s mechanism of action and competitive landscape
  • A risk factor section addressing FDA approval uncertainty and patent expiration

SIC 8731 (Commercial Physical and Biological Research) applies to contract research organisations (CROs) and companies that derive the majority of their revenue from research services rather than product sales. A Hong Kong biotech that licenses its drug candidates to a third party for commercialisation may legitimately use SIC 8731, but only if its revenue from licensing fees and milestones exceeds 50% of total revenue. The SEC’s 2024 comment letter database shows that 14 biotech issuers were required to reclassify from SIC 8731 to SIC 2834 after the SEC determined that their revenue model was primarily product-based.

The NAICS code for the same issuer would be NAICS 325412 (Pharmaceutical Preparation Manufacturing) for a product company or NAICS 541711 (Research and Development in Biotechnology) for a research-stage entity. The US Patent and Trademark Office uses NAICS 541711 to determine eligibility for the Patent Term Extension programme, which can add up to five years of patent life for a drug. A Hong Kong biotech that incorrectly uses NAICS 325412 may inadvertently lose the ability to claim patent term extensions for its US patents.

SPAC Targets and Industry Classification

For a Hong Kong company merging with a US-listed SPAC, the SIC code of the combined entity is determined at the time of the business combination filing (Form S-4 or F-4). The SPAC itself typically uses SIC 6770 (Blank Checks), but the de-SPAC entity must adopt a new code reflecting its actual business. The SEC’s 2023 SPAC rule amendments (Release 33-11280) require that the proxy statement or registration statement include a discussion of the industry classification and the basis for its selection.

A Hong Kong electric vehicle (EV) manufacturer merging with a SPAC must choose between SIC 3711 (Motor Vehicles and Passenger Car Bodies) and SIC 3699 (Electrical Machinery, Equipment, and Supplies, Not Elsewhere Classified). SIC 3711 subjects the issuer to the SEC’s industry guide for automotive companies, which requires disclosure of manufacturing capacity, supply chain risks, and warranty reserves. SIC 3699, used by some battery and component suppliers, requires less granular disclosure but may be challenged by the SEC if the issuer’s primary activity is vehicle assembly.

The NAICS code for the same EV manufacturer would be NAICS 336111 (Automobile Manufacturing) or NAICS 335910 (Battery Manufacturing). The US Department of Energy uses NAICS codes to determine eligibility for grants under the Inflation Reduction Act (IRA) of 2022. A Hong Kong EV manufacturer that selects NAICS 336111 may qualify for IRA credits for domestic manufacturing, but only if it can demonstrate that a substantial portion of its supply chain is located in the US. This classification decision has real cash flow implications: IRA credits for EV manufacturing can reach USD 7,500 per vehicle, per the IRS’s 2024 guidance under Section 30D.

Operational Mechanics and Best Practices for the Filing Process

The selection of SIC and NAICS codes is not a one-time event. The codes must be consistent across the F-1 or S-1 registration statement, the underwriting agreement, and the issuer’s ongoing reporting obligations under the Securities Exchange Act of 1934.

Consistency Across Filings and Jurisdictions

The SEC’s EDGAR system requires that the SIC code be entered in the submission header (Submission Type field). Once the F-1 is declared effective, the code is locked for the issuer’s CIK (Central Index Key) and cannot be changed without filing a Form 8-K (for domestic issuers) or Form 6-K (for foreign private issuers) disclosing the change. A Hong Kong issuer that discovers a classification error post-IPO must file a Form 6-K within four business days of the change, per the SEC’s 2022 guidance on Form 6-K obligations.

The NAICS code, while not embedded in the EDGAR header, must be included in the business description section of the prospectus (Item 101 of Regulation S-K). The SEC’s Division of Corporation Finance has issued comment letters to at least 12 Hong Kong issuers since 2023 requesting that the NAICS code be reconciled with the SIC code and the issuer’s Hong Kong business registration certificate. The Hong Kong Companies Registry assigns a business code under the Business Registration Ordinance (Cap. 310) that must be consistent with the NAICS code for the issuer’s primary activities in Hong Kong.

Timing of the Classification Decision

The optimal time to select SIC and NAICS codes is during the pre-filing conference with the SEC staff, which is available to all foreign private issuers under the SEC’s 2023 guidance. During this confidential meeting, the issuer’s legal counsel can present the proposed codes and receive informal feedback from the reviewing office. The SEC’s SLB 14M encourages issuers to use this process to avoid post-filing reclassification.

For a Hong Kong issuer that has already filed a confidential draft registration statement (DRS) under the EDGAR confidential submission process, changing the SIC code mid-stream requires withdrawing the existing DRS and resubmitting with the new code. This resets the SEC’s 30-day review clock and may trigger a new comment letter cycle. The SEC’s 2024 filing data shows that 8% of F-1 filings from Hong Kong issuers involved a mid-stream SIC code change, adding an average of 47 days to the review process.

Industry-Specific Disclosure Requirements

Once the SIC code is selected, the issuer must comply with all industry-specific disclosure requirements under Regulation S-K. For example, an issuer using SIC 4911 (Electric Services) must disclose rate-making proceedings, fuel cost adjustment clauses, and environmental liabilities under Item 103. A Hong Kong energy company listing on the NYSE that selects SIC 4911 must also comply with the SEC’s industry guide for electric utilities, which requires a 10-year summary of operating statistics.

For issuers in the technology sector (SIC 7370–7379), the SEC’s 2024 guidance on cybersecurity disclosures (Item 106 of Regulation S-K) applies. A Hong Kong software company must disclose its cybersecurity risk management programme, board oversight of cyber risks, and any material cybersecurity incidents in the prior three fiscal years. The NAICS code for the same issuer (e.g., NAICS 511210, Software Publishers) determines whether the issuer must also comply with the US Department of Commerce’s export control regulations under the Export Administration Regulations (EAR).

Actionable Takeaways for CFOs and Counsel

  1. Conduct a pre-filing classification audit that maps the issuer’s Hong Kong business registration code (under Cap. 310) to the proposed SIC and NAICS codes, and reconcile any discrepancies before the first DRS submission.
  2. Request a pre-filing conference with the SEC’s Division of Corporation Finance to obtain informal staff feedback on the proposed SIC code, reducing the risk of post-filing reclassification and the associated 6–10 week delay.
  3. Ensure that the NAICS code is consistent with the issuer’s audited revenue breakdown and that the primary revenue stream (≥50% of total revenue) drives the classification, not a high-growth secondary segment.
  4. For biotech and life sciences issuers, prepare a detailed revenue model analysis that distinguishes between product sales and research service revenue to support the SIC 2834 versus SIC 8731 decision.
  5. For SPAC targets, confirm that the de-SPAC entity’s SIC code is selected at the time of the F-4 filing and that the proxy statement includes a clear rationale for the classification, referencing the SEC’s 2023 SPAC rule amendments.